Julia Varghese
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Julia Varghese has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Luke Y. C. Chen
Division of Hematology University of British Columbia Vancouver British Columbia Canada
4 shared publications Erica Peterson
University of British Columbia
2 shared publications- Mark Trinder
Department of Pathology and Laboratory Medicine University of British Columbia Vancouver British Columbia Canada
2 shared publications - Afsaneh Panahi
British Columbia Cancer, Vancouver Centre, Vancouver, BC, Canada
1 shared publication Andre Mattman
Department of Pathology and Laboratory Medicine, University of British Columbia, Canada
1 shared publication- Andrew A. Y. Chen
Department of Biochemistry and Molecular Biology, Dalhousie University Coastal Program for Rare Inflammatory Diseases, Nova Scotia Health Halifax Nova Scotia Canada
1 shared publication
Latest Publications
- 3 August 2026
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 22 (8) , 941-948
Castleman disease: application of modern classification in a Canadian center
1. Castleman disease (CD) is a rare disease characterized by lymphadenopathy and a wide range of clinical manifestations ranging from focal lymphadenopathy to diffuse lymphoproliferation, systemic ...
- 3 August 2026
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 22 (8) , 941-948
Castleman disease: application of modern classification in a Canadian center
1. Castleman disease (CD) is a rare disease characterized by lymphadenopathy and a wide range of clinical manifestations ranging from focal lymphadenopathy to diffuse lymphoproliferation, systemic ...
- 28 May 2026
- Published by Elsevier in Leukemia Research
- Vol. 167, 108254
Determinants of clinical trial participation in multiple myeloma: A population-based cohort study from British Columbia
- 28 May 2026
- Published by Elsevier in Leukemia Research
- Vol. 167, 108254
Determinants of clinical trial participation in multiple myeloma: A population-based cohort study from British Columbia
- Open Access
- 2 April 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (7) , 1478-1483
Lenalidomide‐Dexamethasone as an Effective and Well‐Tolerated Treatment Option for Refractory Rosai‐Dorfman‐Destombes Disease: A Clinical and Pharmacophenomic Study
A combined clinical and computational pharmacophenomic study from the Coastal Rare Inflammatory Diseases Program and Every Cure.
- 2 April 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (7) , 1478-1483
Open AccessLenalidomide‐Dexamethasone as an Effective and Well‐Tolerated Treatment Option for Refractory Rosai‐Dorfman‐Destombes Disease: A Clinical and Pharmacophenomic Study
A combined clinical and computational pharmacophenomic study from the Coastal Rare Inflammatory Diseases Program and Every Cure.
- 5 November 2025
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (4) , 209-218
Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database
- 5 November 2025
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (4) , 209-218
Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database
- Open Access
- 8 September 2025
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 1 (4)
Treatment of severe refractory immune neutropenia with ruxolitinib: Two cases
Two adult patients with severe immune neutropenia refractory to standard therapies achieved durable remission following treatment with the JAK inhibitor ruxolitinib. This report highlights the potential of JAK–STAT pathway inhibition for managing G-CSF and steroid-refractory immune-mediated neutropenia.
- 8 September 2025
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 1 (4)
Open AccessTreatment of severe refractory immune neutropenia with ruxolitinib: Two cases
Two adult patients with severe immune neutropenia refractory to standard therapies achieved durable remission following treatment with the JAK inhibitor ruxolitinib. This report highlights the potential of JAK–STAT pathway inhibition for managing G-CSF and steroid-refractory immune-mediated neutropenia.
- 1 July 2020
- Published by Elsevier in Clinica Chimica Acta
- Vol. 506, 228-235
Clinical utility of serum IgG4 measurement
- 1 July 2020
- Published by Elsevier in Clinica Chimica Acta
- Vol. 506, 228-235
Clinical utility of serum IgG4 measurement